Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
R J Macaulay1, W Wang, J Dimitroulakos
1Department of Pathology, University of Saskatchewan, Saskatoon, Canada. macaulay@duke.usask.ca
Abstract:
Medulloblastoma is a malignant paediatric central nervous system tumor with a poor prognosis, stimulating the evaluation of improved treatment strategies. Lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, is currently used to treat patients with hypercholesterolemia. This compound also inhibits the production of non-steroidal mevalonate derivatives that are implicated in the control of cellular proliferation, and can induce cell-cycle arrest in vitro. We recently showed that lovastatin inhibited growth and promoted apoptosis of neuroblastoma, the peripheral nervous system 'cousin' of medulloblastoma. Therefore the potential of lovastatin as a possible anticancer drug against medulloblastoma was evaluated in vitro. Four medulloblastoma cell lines, Daoy, UW228, D341 Med and D283 Med, were treated with 1-40 microM of lovastatin in vitro. Analysis of cell morphologic changes, cell viability, DNA fragmentation and flow cytometry in all four cell lines showed growth inhibition and induction of apoptosis with lovastatin treatment. As little as 10 microM of lovastatin was sufficient to cause a marked reduction in cell numbers, and more than 20 microM of lovastatin induced >90% cells to undergo apoptosis, after intervals ranging between 36 and 96 h, depending on the cell line. Lovastatin induced apoptosis in these cell lines was concomitant with cell cycle arrest in G1. The attached cell lines UW228 and Daoy were more sensitive to lovastatin than D283 Med and D341 Med. Daoy cells which survived several cycles of lovastatin treatment could still be induced to undergo apoptosis after longer treatment times. The efficient induction of apoptosis by lovastatin favours this drug as a potential new avenue of therapeutic intervention for medulloablastoma.
Insights
Lovastatin, a cholesterol-lowering drug, effectively inhibits medulloblastoma growth and induces apoptosis in cancer cells. This finding suggests lovastatin as a potential therapeutic agent for treating this aggressive pediatric brain tumor.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Medulloblastoma is a highly malignant pediatric central nervous system tumor with a poor prognosis.
- Current treatment strategies require improvement, necessitating the evaluation of novel therapeutic agents.
- Lovastatin, a statin used for hypercholesterolemia, inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase and affects cellular proliferation pathways.
Purpose of the Study:
- To evaluate the potential of lovastatin as an anticancer drug against medulloblastoma.
- To investigate the in vitro effects of lovastatin on medulloblastoma cell lines, focusing on growth inhibition and apoptosis induction.
Main Methods:
- Four human medulloblastoma cell lines (Daoy, UW228, D341 Med, D283 Med) were treated with varying concentrations of lovastatin (1-40 microM).
- Cell morphology, viability, DNA fragmentation, and cell cycle progression were analyzed using flow cytometry.
- Apoptosis induction and cell cycle arrest were assessed at different time intervals (36-96 hours).
Main Results:
- Lovastatin treatment resulted in significant growth inhibition and apoptosis induction across all four medulloblastoma cell lines.
- Concentrations as low as 10 microM reduced cell numbers, while over 20 microM induced >90% apoptosis.
- Apoptosis was accompanied by cell cycle arrest in the G1 phase; UW228 and Daoy cells were more sensitive than D283 Med and D341 Med.
Conclusions:
- Lovastatin demonstrates potent in vitro anticancer activity against medulloblastoma by inducing apoptosis and cell cycle arrest.
- The drug's ability to efficiently induce apoptosis suggests it as a promising therapeutic candidate for medulloblastoma.
- Further investigation into lovastatin as a novel therapeutic intervention for medulloblastoma is warranted.
